Differential roles of p300 and PCAF acetyltransferases in muscle differentiation

被引:365
作者
Puri, PL
Sartorelli, V
Yang, XJ
Hamamori, Y
Ogryzko, VV
Howard, BH
Kedes, L
Wang, JYJ
Graessmann, A
Nakatani, Y [1 ]
Levrero, M
机构
[1] NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA
[2] Univ Rome La Sapienza, Gene Express Lab, Fdn Andrea Cesalpino, Policlin Umberto 1,Ist Clin Med 1, I-00161 Rome, Italy
[3] Univ So Calif, Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA
[4] Univ Brescia, Sch Med, Inst Chem, I-25100 Brescia, Italy
[5] Free Univ Berlin, Inst Biochem & Mol Biol, Berlin 33, Germany
[6] Univ Cagliari, Ist Med Interna, I-09124 Cagliari, Italy
[7] Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA
关键词
D O I
10.1016/S1097-2765(00)80005-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PCAF is a histone acetyltransferase that associates with p300/CBP and competes with E1A for access to them. While exogenous expression of PCAF potentiates both MyoD-directed transcription and myogenic differentiation, PCAF inactivation by anti-PCAF antibody microinjection prevents differentiation. MyoD interacts directly with both p300/CBP and PCAF, forming a multimeric protein complex on the promoter elements. Viral transforming factors that interfere with muscle differentiation disrupt this complex without affecting the MyoD-DNA interaction, indicating functional significance of the complex formation. Exogenous expression of PCAF or p300 promotes p21 expression and terminal cell-cycle arrest. Both of these activities are dependent on the histone acetyltransferase activity of PCAF, but not on that of p300. These results indicate that recruitment of histone acetyltransferase activity of PCAF by MyoD, through p300/ CBP, is crucial for activation of the myogenic program.
引用
收藏
页码:35 / 45
页数:11
相关论文
共 49 条
  • [1] ACTIVATION OF CAMP AND MITOGEN RESPONSIVE GENES RELIES ON A COMMON NUCLEAR FACTOR
    ARIAS, J
    ALBERTS, AS
    BRINDLE, P
    CLARET, FX
    SMEAL, T
    KARIN, M
    FERAMISCO, J
    MONTMINY, M
    [J]. NATURE, 1994, 370 (6486) : 226 - 229
  • [2] Recruitment of p300/CBP in p53-dependent signal pathways
    Avantaggiati, ML
    Ogryzko, V
    Gardner, K
    Giordano, A
    Levine, AS
    Kelly, K
    [J]. CELL, 1997, 89 (07) : 1175 - 1184
  • [3] The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300
    Avantaggiati, ML
    Carbone, M
    Graessmann, A
    Nakatani, Y
    Howard, B
    Levine, AS
    [J]. EMBO JOURNAL, 1996, 15 (09) : 2236 - 2248
  • [4] The CBP co-activator is a histone acetyltransferase
    Bannister, AJ
    Kouzarides, T
    [J]. NATURE, 1996, 384 (6610) : 641 - 643
  • [5] Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation
    Brownell, JE
    Zhou, JX
    Ranalli, T
    Kobayashi, R
    Edmondson, DG
    Roth, SY
    Allis, CD
    [J]. CELL, 1996, 84 (06) : 843 - 851
  • [6] Special HATs for special occasions: Linking histone acetylation to chromatin assembly and gene activation
    Brownell, JE
    Allis, CD
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (02) : 176 - 184
  • [7] CARUSO M, 1993, ONCOGENE, V8, P267
  • [8] Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
    Chen, HW
    Lin, RJ
    Schiltz, RL
    Chakravarti, D
    Nash, A
    Nagy, L
    Privalsky, ML
    Nakatani, Y
    Evans, RM
    [J]. CELL, 1997, 90 (03) : 569 - 580
  • [9] Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation
    Eckner, R
    Yao, TP
    Oldread, E
    Livingston, DM
    [J]. GENES & DEVELOPMENT, 1996, 10 (19) : 2478 - 2490
  • [10] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825